WATERTOWN, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (NASDAQ: ACUS) today reported financial results for the quarter ended March 31, 2007 and commented on operational priorities and progress, including an NDA submission in Q4 2007 for its lead product candidate, Imagify™ (perflubutane polymer microspheres), a cardiovascular drug in late-stage development for use in screening for coronary artery disease.
